Columbus Hill Capital Management L.P. Boosts Stock Holdings in Humana Inc. $HUM

Columbus Hill Capital Management L.P. lifted its stake in Humana Inc. (NYSE:HUM) by 9.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 172,854 shares of the insurance provider’s stock after purchasing an additional 14,700 shares during the quarter. Humana comprises approximately 5.9% of Columbus Hill Capital Management L.P.’s holdings, making the stock its 8th largest position. Columbus Hill Capital Management L.P. owned 0.14% of Humana worth $44,971,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of HUM. Unison Advisors LLC grew its holdings in shares of Humana by 0.4% during the third quarter. Unison Advisors LLC now owns 10,137 shares of the insurance provider’s stock valued at $2,646,000 after buying an additional 37 shares during the last quarter. Insigneo Advisory Services LLC increased its holdings in Humana by 3.0% in the 3rd quarter. Insigneo Advisory Services LLC now owns 1,484 shares of the insurance provider’s stock worth $386,000 after buying an additional 43 shares in the last quarter. Synovus Financial Corp raised its position in Humana by 2.0% in the 3rd quarter. Synovus Financial Corp now owns 2,278 shares of the insurance provider’s stock worth $593,000 after buying an additional 45 shares during the last quarter. Private Wealth Management Group LLC lifted its position in Humana by 47.5% during the third quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after purchasing an additional 48 shares during the period. Finally, Ossiam lifted its holdings in shares of Humana by 1.6% during the 2nd quarter. Ossiam now owns 4,375 shares of the insurance provider’s stock valued at $1,070,000 after buying an additional 71 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of HUM stock opened at $165.38 on Friday. The company has a market capitalization of $19.85 billion, a P/E ratio of 16.84, a P/E/G ratio of 1.76 and a beta of 0.44. The company’s 50-day simple moving average is $212.90 and its two-hundred day simple moving average is $248.22. Humana Inc. has a one year low of $163.60 and a one year high of $315.35. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.00.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, beating the consensus estimate of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The firm had revenue of $32.64 billion during the quarter, compared to the consensus estimate of $32.08 billion. During the same period in the previous year, the company posted ($2.16) earnings per share. The firm’s quarterly revenue was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, equities analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend is Friday, March 27th. Humana’s payout ratio is currently 36.05%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Evercore dropped their price target on shares of Humana from $260.00 to $180.00 in a research note on Thursday, February 12th. Morgan Stanley set a $146.00 price target on Humana in a research note on Thursday, February 12th. Cantor Fitzgerald cut their price objective on Humana from $290.00 to $201.00 and set a “neutral” rating for the company in a research report on Thursday, February 12th. Barclays cut their target price on shares of Humana from $245.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Finally, JPMorgan Chase & Co. decreased their price objective on Humana from $274.00 to $180.00 and set a “neutral” rating on the stock in a research report on Friday, February 13th. Seven research analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $225.48.

Insider Transactions at Humana

In other Humana news, insider Sanjay K. Shetty acquired 810 shares of the stock in a transaction dated Monday, February 23rd. The stock was purchased at an average price of $185.21 per share, with a total value of $150,020.10. Following the transaction, the insider directly owned 11,657 shares of the company’s stock, valued at $2,158,992.97. This trade represents a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.37% of the company’s stock.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.